8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
8-K:梯瓦公佈2024年第三季度強勁的財務業績,由仿製藥業績和創新投資組合增長帶動;上調了2024年財務展望,包括收入、調整後的息稅折舊攤銷前利潤和非公認會計准則每股收益